Peptidi

Bis-dPEG®4-Acid is a PEG polymer categorised as homobifunctional PEG (X-PEG X). Used as a linker, bis-dPEG®4-Acid is used to attached PEG to proteins, peptides, oligonucleotides, nanoparticles and small molecules via pegylation, a bioconjugation technique.

A synthetic peptide for use as a blocking control in assays to test for specificity of Ard1b antibody, catalog no. 70R-8794

A synthetic peptide for use as a blocking control in assays to test for specificity of GSTM1 antibody, catalog no. 70R-8515

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP4A22 antibody, catalog no. 70R-6524

Bis-dPEG®13-PFP Ester is a PEG polymer categorised as homobifunctional PEG (X-PEG X). Used as a linker, bis-dPEG®13-PFP Ester is used to attached PEG to proteins, peptides, oligonucleotides, nanoparticles and small molecules via pegylation, a bioconjugation technique.

A synthetic peptide for use as a blocking control in assays to test for specificity of Cdx1 antibody, catalog no. 70R-8239

A synthetic peptide for use as a blocking control in assays to test for specificity of SPATA12 antibody, catalog no. 70R-9013

Synthetic product of the Hepcidin peptide hormone. Hepcidin in rats is a peptide hormone that plays a key role in the regulation of iron metabolism in the body. Like hepcidin in humans and other mammals, rat hepcidin is produced by the liver and secreted into the bloodstream, where it interacts with other proteins to control the uptake, storage, and distribution of iron.
Rat hepcidin is structurally similar to human hepcidin, with 88% sequence identity. It shares many of the same functional properties as human hepcidin, including the ability to bind to ferroportin, a protein that facilitates the export of iron from cells into the bloodstream, and to inhibit its activity.
In rats, hepcidin expression is regulated by a variety of factors, including iron status, inflammation, and erythropoietic signals. Studies in rats have shown that alterations in hepcidin levels can lead to changes in iron metabolism and the development of iron-related disorders, such as anemia and iron overload.
This product may be useful for the study of hepcidin biology and the regulation of iron metabolism in mammals. It can also provided valuable insights into the mechanisms of iron homeostasis and the development of iron-related diseases in humans.

A synthetic peptide for use as a blocking control in assays to test for specificity of ADH1B antibody, catalog no. 70R-3920

A synthetic peptide for use as a blocking control in assays to test for specificity of RFPL4B antibody, catalog no. 70R-2776

Glucagon (Human) is a recombinant peptide hormone, which is synthesized to mimic the natural glucagon produced by alpha cells in the pancreas. This biopharmaceutical is derived from a DNA recombinant technology source, offering a high level of purity and consistency. Its mode of action involves binding to glucagon receptors on liver cells, stimulating glycogenolysis and gluconeogenesis. This results in the rapid conversion of glycogen into glucose, thereby raising blood sugar levels.Glucagon (Human) is primarily utilized in the treatment of severe hypoglycemia, especially in diabetic patients unable to consume oral glucose due to unconsciousness or confusion. Its application is critical in acute settings where rapid intervention is necessary to prevent neurological damage from prolonged hypoglycemia. Additionally, the research and clinical use of glucagon extend to investigating its potential in counteracting beta-blocker and calcium channel blocker overdoses, where it acts to increase cardiac output. This hormone's pharmaceutical development has provided a crucial tool in both emergency response and broader therapeutic research contexts.

NHS-m-dPEG® (MW = 333) is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. NHS-m-dPEG® (MW = 333) is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

S-Acetyl-dPEG®4-OH is a PEG polymer categorised as monofunctional (OH-PEG-X). Used as a linker, S-Acetyl-dPEG®4-OH is used to attached PEG to proteins, peptides, oligonucleotides, nanoparticles and small molecules via pegylation, a bioconjugation technique.

A synthetic peptide for use as a blocking control in assays to test for specificity of ARHGAP20 antibody, catalog no. 70R-9503

A synthetic peptide for use as a blocking control in assays to test for specificity of DERL3 antibody, catalog no. 70R-6366

A synthetic peptide for use as a blocking control in assays to test for specificity of ATP6V1G2 antibody, catalog no. 70R-9529

A synthetic peptide for use as a blocking control in assays to test for specificity of PPME1 antibody, catalog no. 70R-3708

A synthetic peptide for use as a blocking control in assays to test for specificity of Pde4d antibody, catalog no. 70R-9419

A synthetic peptide for use as a blocking control in assays to test for specificity of RTCD1 antibody, catalog no. 70R-4721

A synthetic peptide for use as a blocking control in assays to test for specificity of NRP1 antibody, catalog no. 70R-9671

A synthetic peptide for use as a blocking control in assays to test for specificity of DOK5 antibody, catalog no. 70R-3341

A synthetic peptide for use as a blocking control in assays to test for specificity of MFSD8 antibody, catalog no. 70R-9335

Suc-Leu-Leu-Val-Tyr-AMC is a peptide that is an activator of ion channels. It can be used to study the effects of ion channel activation on various cells and tissues. Suc-Leu-Leu-Val-Tyr-AMC has also been shown to inhibit ligand binding to some receptors, such as the acetylcholine receptor. This peptide can also be used as a research tool for pharmacology, protein interactions, and antibody production.

A synthetic peptide for use as a blocking control in assays to test for specificity of MITD1 antibody, catalog no. 70R-4506

A synthetic peptide for use as a blocking control in assays to test for specificity of CLEC4G antibody, catalog no. 70R-7085

A synthetic peptide for use as a blocking control in assays to test for specificity of Pnrc2 antibody, catalog no. 70R-9468

A synthetic peptide for use as a blocking control in assays to test for specificity of MPP7 antibody, catalog no. 70R-2195

A synthetic peptide for use as a blocking control in assays to test for specificity of TMPRSS5 antibody, catalog no. 70R-6998

A synthetic peptide for use as a blocking control in assays to test for specificity of EPSTI1 antibody, catalog no. 70R-7096

A synthetic peptide for use as a blocking control in assays to test for specificity of Il5 antibody, catalog no. 70R-9263

A synthetic peptide for use as a blocking control in assays to test for specificity of Slc9a7 antibody, catalog no. 70R-9602

A synthetic peptide for use as a blocking control in assays to test for specificity of Arpc4 antibody, catalog no. 70R-7971

A synthetic peptide for use as a blocking control in assays to test for specificity of POGK antibody, catalog no. 70R-8328

A synthetic peptide for use as a blocking control in assays to test for specificity of TRIT1 antibody, catalog no. 70R-7956

A synthetic peptide for use as a blocking control in assays to test for specificity of PCDHA10 antibody, catalog no. 70R-6165

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM92B antibody, catalog no. 70R-3362

A synthetic peptide for use as a blocking control in assays to test for specificity of MRTO4 antibody, catalog no. 70R-2933

A synthetic peptide for use as a blocking control in assays to test for specificity of C1QTNF1 antibody, catalog no. 70R-7173

A synthetic peptide for use as a blocking control in assays to test for specificity of FBXO28 antibody, catalog no. 70R-3792

CNP-53 is a Research Tool for the study of protein interactions, pharmacology and cell biology. It is an activator that interacts with Ligand Receptor and Cell Biology. CNP-53 is a peptide with a molecular weight of 5310.1 Da, which is purified to be 99% pure. This product is suitable for use in research as well as in clinical trials and has been shown to inhibit ion channels and high purity proteins.

A synthetic peptide for use as a blocking control in assays to test for specificity of CENPB antibody, catalog no. 70R-5526

A synthetic peptide for use as a blocking control in assays to test for specificity of CSTB antibody, catalog no. 70R-2262

Kv1.3 channel blocker

A synthetic peptide for use as a blocking control in assays to test for specificity of CHRAC1 antibody, catalog no. 70R-7966

A synthetic peptide for use as a blocking control in assays to test for specificity of Ubl3 antibody, catalog no. 70R-9433

A synthetic peptide for use as a blocking control in assays to test for specificity of LRRC37A3 antibody, catalog no. 70R-7010

A synthetic peptide for use as a blocking control in assays to test for specificity of HSPA8 antibody, catalog no. 70R-4109

A synthetic peptide for use as a blocking control in assays to test for specificity of C2orf25 antibody, catalog no. 70R-2461

A synthetic peptide for use as a blocking control in assays to test for specificity of CAP1 antibody, catalog no. 70R-5729

SARS Coronavirus is an enveloped virus containing 3 outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein takes part in the virus infection cycle and is the primary target of neutralizing antibodies. The recombinant SARS Spike containing a total of 220 amino acids (306-515) and having a calculated M.W. of 24.8 kDa.SARS Spike  is fused to a 6 amino acid His-tag at C-terminus, and is purified by proprietary chromatographic techniques. Of a HEK293 source the formulation of the SARS Spike (306-515) solution (0.5mg/ml) contains Phosphate-Buffered Saline (pH 7.4) and 10% Glycerol.
One-Letter Formula: DGSMRVVPSG DVVRFPNITN LCPFGEVFNA TKFPSVYAWE RKKISNCVAD YSVLYNSTFF STFKCYGVSA TKLNDLCFSN VYADSFVVKG DDVRQIAPGQ TGVIADYNYK LPDDFMGCVL AWNTRNIDAT STGNYNYKYR YLRHGKLRPF ERDISNVPFS PDGKPCTPPA LNCYWPLNDY GFYTTTGIGY QPYRVVVLSF ELLNAPATVC GPKLHHHHHH

A synthetic peptide for use as a blocking control in assays to test for specificity of Csnk1g1 antibody, catalog no. 70R-8209

Sarafotoxin S6b, sourced from the venom of the Atractaspis engaddensis snake family, is one of four (S6a-d) isopeptides of the Sarafotoxins. This product is a synthetically produced toxin, containing disulfide bonds between Cys1-Cys15 and Cys3-Cys11.Due to their structural and functional homology to the endothelin peptides, Sarafotoxins can enhance vasoconstriction through stimulating the class A G-protein-coupled, endothelin ETA and ETB receptors. This in turn leads to left ventricular dysfunction and bronchoconstriction.
As the most potent Sarafotoxin, sarafotoxin S6b binds to both ETA and ETB receptors with a similar affinity to Endothelin-1. This is evident as when given to mice intravenously, sarafotoxin S6b caused cardiac arrest and death in mice almost immediately. Additional characteristics of S6b is its matrix metalloproteinase inhibitory activity due to it exhibiting a fold which is also found in the core region of tissue inhibitors of metalloproteinases (TIMPs).
Sarafotoxin S6b can be used as a pharmacological reagent to study the interactions of Endothelins and their corresponding receptors. This product is available as a 0.1mg vial.

A synthetic peptide for use as a blocking control in assays to test for specificity of TAF15 antibody, catalog no. 70R-4632

A synthetic peptide for use as a blocking control in assays to test for specificity of JPH1 antibody, catalog no. 70R-1819

A synthetic peptide for use as a blocking control in assays to test for specificity of IDE antibody, catalog no. 70R-7840

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP46A1 antibody, catalog no. 70R-7130

A synthetic peptide for use as a blocking control in assays to test for specificity of VPS54 antibody, catalog no. 70R-3690

A synthetic peptide for use as a blocking control in assays to test for specificity of DAP3 antibody, catalog no. 70R-10345

Amino-dPEG®8-t-boc-hydrazide is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. Amino-dPEG®8-t-boc-hydrazide is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

A synthetic peptide for use as a blocking control in assays to test for specificity of PYGB antibody, catalog no. 70R-2554

A synthetic peptide for use as a blocking control in assays to test for specificity of RIOK2 antibody, catalog no. 70R-3721

A synthetic peptide for use as a blocking control in assays to test for specificity of FRZB antibody, catalog no. 70R-9273

Prolactin-Releasing Peptide (Human) is a peptide that belongs to the class of inhibitors. It is a protein inhibitor that binds to the receptor and inhibits the activation of the receptor by its ligand. The binding of this peptide to the receptor prevents it from transmitting signals to other cells, thereby blocking cell function. Prolactin-Releasing Peptide (Human) has been shown to inhibit ion channels and can be used as a research tool in cell biology and pharmacology studies. This product is high purity and has not been shown to have any side effects on humans or animals when administered at therapeutic doses.

A synthetic peptide for use as a blocking control in assays to test for specificity of UBQLN1 antibody, catalog no. 70R-3478

A synthetic peptide for use as a blocking control in assays to test for specificity of Itgb1 antibody, catalog no. 70R-9607

A synthetic peptide for use as a blocking control in assays to test for specificity of TRPV4 antibody, catalog no. 70R-5169

A synthetic peptide for use as a blocking control in assays to test for specificity of ZBTB11 antibody, catalog no. 70R-8309

Prolactin Mouse is a cell-based assay that detects apoptosis-inducing factor in the cell culture. Prolactin Mouse is a homogenous, fluorescence-based assay that can be used to study the effects of drugs on cell growth and apoptosis. The protocol involves adding prolactin mouse cells to a 96-well plate, incubating the cells at 37°C for 2 hours, and then adding an agent to induce apoptosis. The cells are then incubated for 24 hours at 37°C with 5% CO2. After this time, the cells are stained with Annexin V and 7AAD antibodies, which bind to phosphatidylserine (PS) on the outer leaflet of the plasma membrane. These antibodies form a complex with PS that can be detected by flow cytometry or microscopy after staining with fluorescent dyes. Prolactin Mouse can also be used for treatments such as endometriosis and mitogen-activated protein kinase

A synthetic peptide for use as a blocking control in assays to test for specificity of LOC339977 antibody, catalog no. 70R-6659

A synthetic peptide for use as a blocking control in assays to test for specificity of FBXO42 antibody, catalog no. 70R-3602

A synthetic peptide for use as a blocking control in assays to test for specificity of SOHLH1 antibody, catalog no. 70R-4217

A synthetic peptide for use as a blocking control in assays to test for specificity of RASGEF1C antibody, catalog no. 70R-5811

A synthetic peptide for use as a blocking control in assays to test for specificity of GEMIN4 antibody, catalog no. 70R-2035

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP1A1 antibody, catalog no. 70R-7266

A synthetic peptide for use as a blocking control in assays to test for specificity of FER1L3 antibody, catalog no. 70R-6290

A synthetic peptide for use as a blocking control in assays to test for specificity of Dusp19 antibody, catalog no. 70R-9185

A synthetic peptide for use as a blocking control in assays to test for specificity of PARP10 antibody, catalog no. 70R-8550

A synthetic peptide for use as a blocking control in assays to test for specificity of PRTFDC1 antibody, catalog no. 70R-2718

A synthetic peptide for use as a blocking control in assays to test for specificity of HMBS antibody, catalog no. 70R-3585

gp100 (280-288) A288V HLA-A*0201 antigen peptide – YLEPGPVTV

A synthetic peptide for use as a blocking control in assays to test for specificity of WDFY3 antibody, catalog no. 70R-9011

A synthetic peptide for use as a blocking control in assays to test for specificity of FCRLA antibody, catalog no. 70R-7201

A synthetic peptide for use as a blocking control in assays to test for specificity of C13orf30 antibody, catalog no. 70R-4041

A synthetic peptide for use as a blocking control in assays to test for specificity of SYNCRIP antibody, catalog no. 70R-1309

A synthetic peptide for use as a blocking control in assays to test for specificity of DDX39 antibody, catalog no. 70R-1399

A synthetic peptide for use as a blocking control in assays to test for specificity of DBI antibody, catalog no. 70R-2557

A synthetic peptide for use as a blocking control in assays to test for specificity of CCT7 antibody, catalog no. 70R-5634

A synthetic peptide for use as a blocking control in assays to test for specificity of TBL1XR1 antibody, catalog no. 70R-10391

MAGE-A1 protein:
MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells.
Applications of MAGE-A1 (278-286):
MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.

A synthetic peptide for use as a blocking control in assays to test for specificity of UBE2E2 antibody, catalog no. 70R-2819

A synthetic peptide for use as a blocking control in assays to test for specificity of ZFP57 antibody, catalog no. 20R-1250

A synthetic peptide for use as a blocking control in assays to test for specificity of RFC5 antibody, catalog no. 70R-5530

A synthetic peptide for use as a blocking control in assays to test for specificity of CHEK2 antibody, catalog no. 70R-7835

A synthetic peptide for use as a blocking control in assays to test for specificity of WDR49 antibody, catalog no. 70R-3997

A synthetic peptide for use as a blocking control in assays to test for specificity of TTC14 antibody, catalog no. 70R-4777